# A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults

> **NCT03795441** · PHASE1 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Ad26.RSV.preF

## Key facts

- **NCT ID:** NCT03795441
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-07
- **Primary completion:** 2019-07-28
- **Final completion:** 2019-07-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03795441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03795441, "A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03795441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*